Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Yang Lin1, Tianmin Xu1, Shunqing Zhou1

  • 1Department of Obstetrics and Gynecology, The Second Hospital, Jilin University, Nanguan District, Changchun 130041, China.

Oncotarget
|December 20, 2017
PubMed

Insights

MicroRNA-363 (miR-363) acts as a tumor suppressor in ovarian cancer (OC). Lower miR-363 levels correlate with advanced OC stages and poor prognosis, while its restoration inhibits OC cell growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer (OC) remains a leading cause of cancer-related deaths in women.
  • Understanding the molecular mechanisms driving OC progression is crucial for developing effective therapies.
  • MicroRNAs (miRNAs) are increasingly recognized for their roles in cancer development and progression.

Purpose of the Study:

  • To investigate the role of microRNA-363 (miR-363) in ovarian cancer (OC) progression.
  • To determine the molecular target and mechanism of action of miR-363 in OC.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to assess miR-363 expression in OC tissues and cell lines.
  • Cell proliferation, colony formation, migration, and invasion assays to evaluate the functional role of miR-363.
  • In vivo xenograft tumor models in nude mice to assess the effect of miR-363 on tumor growth.
  • Bioinformatics analysis and dual-luciferase reporter assays to identify and validate the direct target of miR-363.

Main Results:

  • MiR-363 expression was significantly downregulated in OC patient tissues and OC cell lines.
  • Low miR-363 levels were associated with advanced tumor stage, lymph node metastasis, and poorer patient prognosis.
  • Overexpression of miR-363 inhibited OC cell proliferation, colony formation, migration, and invasion in vitro.
  • MiR-363 overexpression reduced tumor growth and weight in vivo.
  • NIN1/RPN12 binding protein 1 homolog (NOB1) was identified as a direct target of miR-363, with its expression inversely correlated to miR-363 levels in OC tissues.

Conclusions:

  • MiR-363 functions as a tumor suppressor in ovarian cancer.
  • MiR-363 inhibits OC progression by directly targeting and suppressing NOB1 expression.
  • Restoring miR-363 levels may represent a potential therapeutic strategy for ovarian cancer.
Keywords:
NOB1miR-363microRNAsovarian cancer

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.1K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K